Device manufacturer, as written on reports
Tandem Diabetes Care: medical device reports filed with FDA
1,373,250 reports name it as the manufacturer of the device involved, 2013–2026.
- 1,373,250
- reports naming it as manufacturer
- 5.3% of all MAUDE reports
- 244,646
- reports, 12 months to August 2026
- 246,982 in the 12 months before
- 88%
- classified as malfunction
- 62.3% across all reports
- 0%
- classified as death, as reported
- 0.9% across all reports
1,373,250 medical device reports received by FDA give Tandem Diabetes Care as the manufacturer of the device involved, 5.3% of the MAUDE database, from May 2013 to August 2026. Manufacturer names are as written on the report; subsidiaries and spelling variants may appear as separate names.
244,646 reports arrived in the 12 months to August 2026, close to the 246,982 of the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are malfunction (88%) and injury (11.9%). Manufacturers are required to report events they learn of, so a large manufacturer with many products in use files many reports. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Brands named most often
| Brand | Device type | Reports | Latest 12 months | Classified as death |
|---|---|---|---|---|
| t:slim X2 Insulin Pump with Control-IQ Technology | Alternate controller enabled insulin infusion pump | 584,122 | 129,119 | 0% |
| t:slim X2 Insulin Pump with Interoperable Technology (with t:connect mobile app) | Alternate controller enabled insulin infusion pump | 267,629 | 11,502 | 0% |
| t:slim X2 Insulin Pump with Basal-IQ Technology | Automated insulin dosing , threshold suspend | 142,635 | 1,916 | 0% |
| t:slim X2 Insulin Pump with Control-IQ+ Technology | Alternate controller enabled insulin infusion pump | 65,297 | 57,936 | 0% |
| Tandem T Slim Insulin Delivery System | Pump, infusion, insulin | 52,251 | 0 | 0.1% |
| t:slim X2 Insulin Pump with Interoperable Technology | Alternate controller enabled insulin infusion pump | 37,128 | 865 | 0% |
| Tandem Mobi Insulin Pump with Control-IQ+ Technology | Alternate controller enabled insulin infusion pump | 36,499 | 31,674 | 0% |
| T Slim G5 System | Pump, infusion, insulin, to be used with invasive glucose sensor | 36,250 | 0 | 0% |
| t:slim G4 system | Pump, infusion, insulin, to be used with invasive glucose sensor | 35,415 | 20 | 0% |
| t:slim X2 Insulin Pump | Pump, infusion, insulin | 31,147 | 86 | 0% |
| Tandem Mobi Insulin Pump with Interoperable Technology | Alternate controller enabled insulin infusion pump | 27,951 | 1,595 | 0% |
| t:slim Insulin Delivery System | Pump, infusion, insulin | 19,276 | 30 | 0.1% |
| Tandem Mobi Insulin Pump with Control-IQ Technology | Alternate controller enabled insulin infusion pump | 15,153 | 9,553 | 0% |
| T Flex Insulin Delivery System | Pump, infusion, insulin | 11,220 | 0 | 0.1% |
| T Slim X2 Basal-Iq Mmol/L | Automated insulin dosing , threshold suspend | 3,120 | 0 | 0% |
| T Slim X2 Insulin Pump With Interoperable Technology With T Connect Mobile A | Alternate controller enabled insulin infusion pump | 2,555 | 0 | 0% |
| Tandem T Flex Insulin Delivery System | Pump, infusion, insulin | 528 | 0 | 0.2% |
| T Slim X2 Basal Iq Mg/Dl | Automated insulin dosing , threshold suspend | 477 | 0 | 0% |
| T Slim X2 Insulin Pump With Interoperable Technology With T Connect Mobile Ap | Alternate controller enabled insulin infusion pump | 453 | 0 | 0% |
| Tandem Mobi Mobile App | Alternate controller enabled insulin infusion pump | 443 | 340 | 0% |
| T Slim X2 Basal-Iq Mg/Dl | Automated insulin dosing , threshold suspend | 435 | 0 | 0% |
| T Slim X2 With Basal-Iq Technology | Alternate controller enabled insulin infusion pump | 414 | 0 | 0% |
| T Slim X2 Insulin Pump With Control-Iq Technology With T Connect Mobile App | Alternate controller enabled insulin infusion pump | 296 | 0 | 0% |
| Tandem T Slim Insulin Delivery Sys | Pump, infusion, insulin | 286 | 0 | 0% |
| Tandem T Slim Insulin Deliver System | Pump, infusion, insulin | 273 | 0 | 0% |
| T Slim X2 Insulin Pump With Interoperable Technology With T Connect Mobi | Alternate controller enabled insulin infusion pump | 184 | 0 | 0% |
| Dexcom G6 Continuous Glucose Monitoring System | Integrated continuous glucose monitoring system, factory calibrated | 43 | 61,710 | 0% |
| Autosoft Xc | Set, administration, intravascular | 1 | 49 | 0% |
| Cartridge | Set, tubing, blood, with and without anti-regurgitation valve | 1 | 0 | 3% |
| Infusion Pump | Pump, infusion, implanted, programmable | 1 | 6 | 3.7% |
Brands with a page on this site, ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Device types
| Product code | Device type | Reports | Share |
|---|---|---|---|
| QFG | Alternate controller enabled insulin infusion pump | 1,042,455 | 75.9% |
| OZO | Automated insulin dosing , threshold suspend | 143,707 | 10.5% |
| LZG | Pump, infusion, insulin | 103,231 | 7.5% |
| OYC | Pump, infusion, insulin, to be used with invasive glucose sensor | 84,320 | 6.1% |
| QBJ | Integrated continuous glucose monitoring system, factory calibrated | 75 | 0% |
| PQF | Sensor, glucose, invasive, non-adjunctive | 20 | 0% |
| QJI | Interoperable automated glycemic controller | 7 | 0% |
| FPA | Set, administration, intravascular | 5 | 0% |
| FRN | Pump, infusion | 5 | 0% |
| OUG | Medical device data system | 3 | 0% |
Reports by month, five years
FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases.
Event type
Grey bar: all 26,136,888 MAUDE reports. Event type is the filer's classification and is not verified by FDA.
Questions about Tandem Diabetes Care reports
How many FDA device reports name Tandem Diabetes Care as manufacturer?
1,373,250 reports through August 2026, 244,646 of them in the latest 12 months.
Which of its brands appear most often?
t:slim X2 Insulin Pump with Control-IQ Technology (584,122), t:slim X2 Insulin Pump with Interoperable Technology (with t:connect mobile app) (267,629), t:slim X2 Insulin Pump with Basal-IQ Technology (142,635), t:slim X2 Insulin Pump with Control-IQ+ Technology (65,297) and Tandem T Slim Insulin Delivery System (52,251).
Which device types does it report on?
alternate controller enabled insulin infusion pump (75.9%), automated insulin dosing , threshold suspend (10.5%), pump, infusion, insulin (7.5%) and pump, infusion, insulin, to be used with invasive glucose sensor (6.1%).
Does a high count say something about the manufacturer?
Not by itself. Manufacturers must file a report for every event they become aware of, so report volume follows the number of devices in use. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. Manufacturer names are pooled after company suffixes (Inc., LLC, GmbH and similar) are dropped; names that read as a person rather than an organisation are never published. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.